Development of a novel targeted therapy using gold nanoparticles for dose enhancement of X-ray irradiation for the treatment of triple-negative breast cancer (Acronym: TaGoNaX)

开发一种新型靶向疗法,使用金纳米粒子增强 X 射线照射的剂量来治疗三阴性乳腺癌(缩写:TaGoNaX)

基本信息

项目摘要

Gold nanoparticles show potential as radiosensitizers in radiation therapy. The first successful experiment using gold nanoparticles to increase the radiosensitivity of tumours in mice after irradiation with X-rays stimulated extended experimental and theoretical investigations. One of the major challenges in this research field is the limited availability of target structures that enables a selective uptake of gold nanoparticles into tumour cells. In this proposal, we will investigate the role of membrane heat shock protein 70 (Hsp70) on tumour cells as a target for an enhanced and selective uptake of gold nanoparticles to enhance the efficacy of X-ray based radiation therapy. The research results can provide quantitative information for the decision of using gold nanoparticle as sensitizers in preclinical and clinical radiation therapy settings. In a first step, the Hsp70-specific antibody cmHsp70.1 will be conjugated to gold nanoparticles with different sizes and shapes (AuNP-cmHsp70.1). The coupling of the cmHsp70.1 antibody to AuNPs should enable a tumour-specific targeting of gold nanoparticles into tumorigenic mouse mammary gland cells (4T1) and primary breast cancer cell cultures derived from patients, as Hsp70 is exclusively expressed on the surface of cancer cells, but not on normal cells. Transmission electron microscopy and dynamic light scattering imaging will image the location and distribution of gold nanoparticles inside the cells. In a second step, an X-ray irradiation of the cells with and without gold nanoparticles will be performed at the radiation facilities at the Klinikum rechts der Isar, Technical University of Munich. In a third step, DNA damage and cell survival will be determined comparatively in irradiated cancer cells with and without AuNPs-cmHsp70.1 and the enhanced physical and biological effects induced by gold nanoparticles and X-rays will be determined quantitatively. The most promising AuNP-cmHsp70.1 conjugates will be tested in orthotopic breast cancer mouse models with respect to their radiosensitizing effects. Parallel to the biological experimental investigations, Monte Carlo radiation transport simulations of dose enhancement of gold nanoparticles irradiated by X-rays provide a quantitative cellular dose in the cancer cells. A mathematical model will be developed to analyse the relationship between the enhanced biological endpoints, such as DNA strand breaks and cell survival fractions and physical radiation doses deposited in the cellular level and in tumour mouse-models. Finally, the radiation dose-response relationship can provide basic information for a better understanding of the mechanisms of gold nanoparticles as sensitizers in radiation therapy of breast cancer.
金纳米颗粒在放射治疗中显示出作为放射增敏剂的潜力。第一个成功的实验使用金纳米粒子增加x射线照射后小鼠肿瘤的放射敏感性,刺激了扩展的实验和理论研究。这一研究领域的主要挑战之一是能够选择性地将金纳米颗粒吸收到肿瘤细胞中的目标结构的有限可用性。在这个提议中,我们将研究膜热休克蛋白70 (Hsp70)在肿瘤细胞上的作用,作为增强和选择性吸收金纳米颗粒的靶标,以提高x射线放射治疗的疗效。研究结果可为临床前和临床放射治疗中是否使用金纳米粒子作为增敏剂提供定量信息。在第一步中,hsp70特异性抗体cmHsp70.1将与不同大小和形状的金纳米颗粒(AuNP-cmHsp70.1)结合。由于Hsp70仅在癌细胞表面表达,而不在正常细胞表面表达,因此cmHsp70.1抗体与AuNPs的偶联应该能够使金纳米颗粒靶向肿瘤特异性地进入致瘤小鼠乳腺细胞(4T1)和来自患者的原发性乳腺癌细胞培养物中。透射电子显微镜和动态光散射成像将对细胞内金纳米颗粒的位置和分布进行成像。在第二步中,将在慕尼黑工业大学Klinikum rechts der Isar的辐射设施中对带有和不带有金纳米粒子的细胞进行x射线照射。第三步,比较辐照癌细胞中unps - cmhsp70.1和unps - cmhsp70.1的DNA损伤和细胞存活率,定量测定金纳米颗粒和x射线诱导的增强物理和生物效应。最有希望的AuNP-cmHsp70.1缀合物将在原位乳腺癌小鼠模型中测试其放射增敏作用。与生物实验研究平行,x射线照射金纳米粒子剂量增强的蒙特卡罗辐射输运模拟提供了癌细胞中的定量细胞剂量。将开发一个数学模型来分析增强的生物端点(如DNA链断裂和细胞存活分数)与沉积在细胞水平和肿瘤小鼠模型中的物理辐射剂量之间的关系。最后,辐射剂量-反应关系可以为更好地理解金纳米颗粒作为增敏剂在乳腺癌放射治疗中的作用机制提供基础信息。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Multi-scale Monte Carlo simulations of gold nanoparticle-induced DNA damages for kilovoltage X-ray irradiation in a xenograft mouse model using TOPAS-nBio
  • DOI:
    10.1186/s12645-021-00099-3
  • 发表时间:
    2021-12-01
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Klapproth, Alexander P.;Schuemann, Jan;Multhoff, Gabriele
  • 通讯作者:
    Multhoff, Gabriele
Gold Nanoparticle Mediated Multi-Modal CT Imaging of Hsp70 Membrane-Positive Tumors
  • DOI:
    10.3390/cancers12051331
  • 发表时间:
    2020-05-01
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Kimm,Melanie A.;Shevtsov,Maxim;Stangl,Stefan
  • 通讯作者:
    Stangl,Stefan
Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70-Positive Tumors for Multimodal Cancer Theranostics.
  • DOI:
    10.1002/smll.201900205
  • 发表时间:
    2019-03
  • 期刊:
  • 影响因子:
    13.3
  • 作者:
    M. Shevtsov;S. Stangl;B. Nikolaev;L. Yakovleva;Y. Marchenko;R. Tagaeva;W. Sievert;E. Pitkin;
  • 通讯作者:
    M. Shevtsov;S. Stangl;B. Nikolaev;L. Yakovleva;Y. Marchenko;R. Tagaeva;W. Sievert;E. Pitkin;
A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
  • DOI:
    10.2147/ijn.s254745
  • 发表时间:
    2020-01-01
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Klapproth, Alexander P.;Shevtsov, Maxim;Multhoff, Gabriele
  • 通讯作者:
    Multhoff, Gabriele
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dr. Stefan Stangl, Ph.D.其他文献

Dr. Stefan Stangl, Ph.D.的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Presymptom: development of a novel machine-learning-derived diagnostic test to rule out infection to enable enhanced clinical care and better targeted anti-microbial use
症状前:开发一种新型的机器学习诊断测试来排除感染,从而加强临床护理和更有针对性的抗菌药物使用
  • 批准号:
    10089281
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Investment Accelerator
Development a novel immnunotherapy for gastric cancer by targeted SMARCA4
通过靶向 SMARCA4 开发一种新型胃癌免疫疗法
  • 批准号:
    23K15047
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Precision Nutrition for Gut Health: Development of a novel seaweed-containing, gut microbiota targeted nutraceutical
肠道健康的精准营养:开发一种新型的含海藻、针对肠道微生物群的营养保健品
  • 批准号:
    2886525
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Studentship
Development of a digital therapeutic targeting anxiety sensitivity to reduce PTSD-SUD in women presenting for emergency care after sexual assault.
开发一种针对焦虑敏感性的数字疗法,以减少性侵犯后寻求紧急护理的女性的 PTSD-SUD。
  • 批准号:
    10449766
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
  • 批准号:
    10759731
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of peptide drug conjugates for cancer therapy
开发用于癌症治疗的肽药物缀合物
  • 批准号:
    10760236
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
  • 批准号:
    10735492
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Discovery and Development of a Benzoquinone Molecule as a Novel Anesthetic
苯醌分子作为新型麻醉剂的发现和开发
  • 批准号:
    10732956
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
宾夕法尼亚大学患者来源的异种移植开发和试验中心
  • 批准号:
    10733231
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
lncRNA Function and Mechanisms during Cardiac Development and Disease
心脏发育和疾病过程中lncRNA的功能和机制
  • 批准号:
    10608600
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了